Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedicitumab + sepalizumab + SBRT in recurrent or metastatic cervical cancer
ChiCTR2300072129Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and zimberelimab in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: objective response rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
disitamab vedotinzimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2300072129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072129.